Opinion|Videos|October 28, 2024
Understanding Your Treatment Options for Advanced Prostate
Key Takeaways
- Advanced prostate cancer treatment requires a personalized approach, considering disease stage, comorbidities, and patient preferences.
- ARPIs have revolutionized treatment, highlighting the need for early and aggressive intervention to improve outcomes.
Panelists discuss how a comprehensive treatment approach for advanced prostate cancer involves considering various patient-specific factors, the transformative role of androgen receptor pathway inhibitors (ARPIs), and the necessity of early and aggressive intervention, while emphasizing the importance of clear communication between oncologists and patients regarding treatment expectations and options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you share your approach to treating advanced prostate cancer?
- What factors do you consider when recommending a particular approach?
- What are ARPIs and how have they changed the treatment landscape for advanced prostate cancer? How important is it to treat it early and aggressively?
- Please describe your treatment process. What were your goals and expectations of treatment? What did your oncologist tell you to expect?
- How did your oncologist walk you through your options and discuss your concerns?
- How can physicians ensure that their patients understand all their options?
- What has your response to treatment been?
Advertisement
Related to this article
Learn why hepatitis B can reactivate during cancer treatment, which therapies increase the risk and how antiviral medicines can help protect liver health.
After her sister’s Hodgkin lymphoma diagnosis, remission and relapse, a caregiver reflects on follow-up care, guilt and finding hope between cancer battles.
After a pancreatic cancer diagnosis upended his life and career, one survivor reflects on treatment, resilience and finding hope more than a decade later.
The American Society of Hematology published 2026 guidelines for adults with myelofibrosis on Oct. 14, 2026, with 10 recommendations on genetic testing, JAK inhibitors, anemia, transplant referral and aspirin.
A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.
Lower income, later diagnosis and gaps in treatment drove most of the excess deaths among rural patients, according to new research.
The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Jemperli for dMMR Locally Advanced Rectal Cancer
2
New Myelofibrosis Guidelines Back Wider Gene Testing at Diagnosis
3
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
4
Gemcitabine Plus BCG Clears Bladder Cancer in 96% of Patients After BCG Failure
5